47 completed, 6 terminated, 4 unknown, 2 withdrawn. 31 Phase 4, 19 Phase 3, 6 Phase 2, 2 Not applicable, 1 Phase 1.
Follow brinzolamide: new trials by email Literature Review of brinzolamide trials Research Report on brinzolamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension Brinzolamide ophthalmic suspension, Azopt® - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 599 | 2021-12-20 | 2024-01-18 |
| To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Padagis LLC | 447 | 2021-05-28 | 2025-04-02 |
| Augmented Macular Pigment-containing Nutraceutical and Central Visual Function Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo - Glaucoma, Glaucoma Eye | Phase 4 | Withdrawn | University of the Incarnate Word | 2021-05-01 | 2022-10-04 | |
| To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Padagis LLC | 495 | 2019-06-24 | 2023-03-06 |
| Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt brinzolamide 1% ophthalmic suspension, Azopt 1% - Glaucoma, Open Angle or Ocular Hypertension | Phase 1 / Phase 2 | Completed | Bausch & Lomb Incorporated | 637 | 2018-02-28 | 2023-05-09 |
| Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma brinzolamide 1%/brimonidine 0.2% fixed combination, Placebo, travoprost 0.004% ophthalmic solution - Glaucoma | Phase 4 | Completed | Novartis Pharmaceuticals | 1 | 2017-09-21 | 2019-02-25 |
| Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Terminated | Alcon Research | 173 | 2016-06-24 | 2019-05-29 |
| Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy Brinzolamide/Brimonidine FC, Brimonidine 0.2%, Artificial tears - Posterior Capsule Opacification, Ocular Hypertension | Phase 4 | Completed | University Hospital of Patras | 79 | 2016-06-20 | 2019-07-16 |
| 24-hr Intraocular Pressure Control With SIMBRINZA ® Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Vehicle - Glaucoma | Phase 4 | Completed | Alcon Research | 162 | 2016-05-23 | 2018-07-02 |
| Stop Retinal Ganglion Cell Dysfunction Study Latanoprost, Bimatoprost, Travoprost - Glaucoma | Phase 3 | Terminated | University of Miami | 28 | 2015-09-01 | 2025-08-26 |
| SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 290 | 2015-08-07 | 2018-11-15 |
| Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, Brinzolamide 10 mg/mL eye drops, suspension, Brimonidine 2 mg/mL eye drops, solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 493 | 2015-04-14 | 2018-07-02 |
| Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon, a Novartis Company | 218 | 2014-12-01 | 2016-12-08 |
| 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 327 | 2014-06-01 | 2015-12-29 |
| Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle | Phase 4 | Completed | Afyon Kocatepe University Hospital | 96 | 2014-01-01 | 2019-05-29 |
| Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Prostaglandin analogue - Ocular Hypertension, Open Angle Glaucoma | Phase 4 | Completed | Alcon Research | 282 | 2013-10-01 | 2015-07-28 |
| Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5% - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 89 | 2013-10-01 | 2015-04-13 |
| Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 4 | Completed | Alcon Research | 307 | 2013-10-01 | 2015-05-14 |
| Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH Latanoprost+Brinzolamide combination, Latanoprost - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Withdrawn | Adapt Produtos Oftalmológicos Ltda. | 2012-12-01 | 2014-12-11 | |
| Clinical Evaluation of Patients With X-linked Retinoschisis Dorzolamide 2% TID or brinzolamide 1% TID - X-linked Retinoschisis, XLRS | Completed | Beacon Therapeutics | 66 | 2012-11-01 | 2017-11-17 |
Showing 20 of 59. Sign in to see all of them.
Ocular Hypertension (44) · Glaucoma (35) · Glaucoma, Open-Angle (35) · Exfoliation Syndrome (1) · Glaucoma, Angle-Closure (1) · Hypertension (1) · Low Tension Glaucoma (1) · Retinoschisis (1)
Alcon Research (36) · Bausch & Lomb Incorporated (2) · Padagis LLC (2) · Adapt Produtos Oftalmológicos Ltda. (1) · Afyon Kocatepe University Hospital (1) · Akron Children's Hospital (1) · Alcon, a Novartis Company (1) · Allergan (1) · Aristotle University Of Thessaloniki (1) · Beacon Therapeutics (1) · Credit Valley EyeCare (1) · Hermann Eye Center (1) · Northwestern Ophthalmic Institute S.C. (1) · Novartis Pharmaceuticals (1) · Peking University First Hospital (1)
United States (20) · Brazil (2) · Canada (2) · Germany (2) · India (2) · Singapore (2) · Argentina (1) · Australia (1) · Belgium (1) · Greece (1) · Japan (1) · Mexico (1) · Russia (1) · South Korea (1)
James Teague, BS, Sr. Clinical Manager (3) · Steve Burmaster, PhD (3) · Abayomi Ogundele, PharmD (1) · Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Anna Grau (1) · Constantinos Georgakopoulos, MD, PhD (1) · Danyel C. Carr, MS, CCRA (1) · Danyel Carr, MS (1) · Devesh K Varma, MD FRCSC (1)
PMID 17191187, PMID 18289898, PMID 18402717, PMID 18538406, PMID 19049301, PMID 19365194, PMID 21048504, PMID 22205835, PMID 23579344, PMID 25336575, PMID 25429421, PMID 25430900, PMID 27450828, PMID 30551202
2008 (1), 2015 (1), 2016 (1), R01EY014957 (1)